The 4 Cardiology High-Yield Concepts That Show Up on Every FNP Board Exam

Cardiology · 3 min read · September 23, 2026

Decoding Heart Murmurs Without the Panic

Heart murmurs are a staple of both family practice and board exams, and they often cause unnecessary anxiety for FNP students. The secret to mastering murmurs for the AANP and ANCC boards is understanding their timing, radiation, and dynamic maneuvers. Remember that systolic murmurs occur between S1 and S2, while diastolic murmurs occur between S2 and S1. Diastolic murmurs are almost always pathologic and warrant an immediate cardiology referral.

To differentiate common systolic murmurs, focus on key physical exam findings. Aortic stenosis produces a harsh, crescendo-decrescendo systolic ejection murmur that radiates to the carotids and is best heard at the right second intercostal space. In contrast, mitral regurgitation presents as a holosystolic, high-pitched blowing murmur that radiates to the axilla.

Board Pearl: The Valsalva maneuver and standing decrease venous return, which decreases the intensity of most murmurs—except for hypertrophic cardiomyopathy (HCM) and mitral valve prolapse (MVP). In HCM, decreased preload brings the ventricular septum closer to the anterior mitral leaflet, making the obstruction and murmur louder.

Navigating Chronic Heart Failure Management Guidelines

Heart failure management is heavily tested because guidelines have evolved significantly over recent years. You must be comfortable with the four pillars of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF): ARNI or ACEi/ARB, beta-blockers (specifically carvedilol, metoprolol succinate, or bisoprolol), mineralocorticoid receptor antagonists (MRAs like spironolactone), and SGLT2 inhibitors (dapagliflozin or empagliflozin).

When a patient with HFrEF presents with worsening dyspnea and peripheral edema, your first step is assessing volume status and optimizing GDMT. Do not just reach for higher doses of loop diuretics without ensuring the patient is on disease-modifying agents that actually reduce mortality.

Board Pearl: SGLT2 inhibitors are now foundational in HFrEF management regardless of whether the patient has type 2 diabetes. Expect board questions testing your knowledge of these dual-benefit medications.

Hypertension staging and Pharmacotherapy Choices

Hypertension guidelines are a game of patient demographics and comorbidities. You need to know when to initiate monotherapy versus dual-agent therapy. According to current guidelines, stage 1 hypertension (130-139/80-89 mmHg) warrants lifestyle modification and medication initiation only if the patient has clinical ASCVD or a 10-year risk of 10% or higher. Stage 2 hypertension (≥140/90 mmHg) requires lifestyle modification and two different-class first-line agents.

First-line options include thiazide diuretics, calcium channel blockers (CCBs), and ACE inhibitors or ARBs. However, compelling indications dictate your choice. For instance, a patient with chronic kidney disease or diabetes with proteinuria must be started on an ACE inhibitor or ARB to provide renal protection.

Board Pearl: Never combine an ACE inhibitor with an angiotensin receptor blocker (ARB) or a direct renin inhibitor due to significantly increased risks of hyperkalemia, hypotension, and acute kidney injury without added mortality benefit.

Recognizing Acute Coronary Syndrome Equivalents

Classic presentation of acute coronary syndrome (ACS)—crushing substernal chest pain radiating to the left arm or jaw—is easy to spot. However, board exams love to test your ability to recognize atypical presentations, especially in vulnerable populations like women, older adults, and patients with diabetes. These individuals frequently present with ACS "equivalents" such as sudden-onset dyspnea, unexplained fatigue, nausea, vomiting, or diaphoresis.

When a patient presents with symptoms suggestive of cardiac ischemia, your immediate priority in the outpatient setting is obtaining a 12-lead ECG and arranging for emergency transport. Do not wait for biomarker results if the ECG shows acute ST-elevation myocardial infarction (STEMI).

Board Pearl: In inferior wall STEMIs (seen in leads II, III, and aVF), avoid administering nitroglycerin if right ventricular infarction is suspected, as profound, refractory hypotension can occur due to preload dependency.

You have what it takes to master cardiology and crush your board exam. Take it one concept at a time, trust your clinical reasoning, and keep moving forward!